Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy

Nour Abuhadra; Ryan Sun; Roland L. Bassett; Lei Huo; Jeffrey T. Chang; Mediget Teshome; Alyson R. Clayborn; Jason B. White; Elizabeth E. Ravenberg; Beatriz E. Adrada; Rosalind P. Candelaria; Wei Yang; Qingqing Ding; W. Fraser Symmans; Banu Arun; Senthil Damodaran; Kimberly B. Koenig; Rachel M. Layman; Bora Lim; Jennifer K. Litton; Alastair Thompson; Naoto T Ueno; Helen Piwnica-Worms; Gabriel N. Hortobagyi; Vicente Valero; Debu Tripathy; Gaiane M. Rauch; Stacy Moulder; Clinton Yam

doi:10.1007/s10637-023-01357-4

Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy

Nour Abuhadra, Ryan Sun, Roland L. Bassett, Lei Huo, Jeffrey T. Chang, Mediget Teshome, Alyson R. Clayborn, Jason B. White, Elizabeth E. Ravenberg, Beatriz E. Adrada, Rosalind P. Candelaria, Wei Yang, Qingqing Ding, W. Fraser Symmans, Banu Arun, Senthil Damodaran, Kimberly B. Koenig, Rachel M. Layman, Bora Lim, Jennifer K. LittonAlastair Thompson, Naoto T Ueno, Helen Piwnica-Worms, Gabriel N. Hortobagyi, Vicente Valero, Debu Tripathy, Gaiane M. Rauch, Stacy Moulder, Clinton Yam

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	391-401
Number of pages	11
Journal	Investigational New Drugs
Volume	41
Issue number	3
DOIs	https://doi.org/10.1007/s10637-023-01357-4
State	Published - Jun 2023

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

MD Anderson CCSG core facilities

Biostatistics Resource Group

Access to Document

10.1007/s10637-023-01357-4

Cite this

Abuhadra, N., Sun, R., Bassett, R. L., Huo, L., Chang, J. T., Teshome, M., Clayborn, A. R., White, J. B., Ravenberg, E. E., Adrada, B. E., Candelaria, R. P., Yang, W., Ding, Q., Symmans, W. F., Arun, B., Damodaran, S., Koenig, K. B., Layman, R. M., Lim, B., ... Yam, C. (2023). Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Investigational New Drugs, 41(3), 391-401. https://doi.org/10.1007/s10637-023-01357-4

Abuhadra, N, Sun, R , Bassett, RL , Huo, L, Chang, JT, Teshome, M, Clayborn, AR, White, JB, Ravenberg, EE, Adrada, BE , Candelaria, RP , Yang, W , Ding, Q , Symmans, WF , Arun, B , Damodaran, S , Koenig, KB , Layman, RM , Lim, B , Litton, JK, Thompson, A, Ueno, NT, Piwnica-Worms, H, Hortobagyi, GN, Valero, V , Tripathy, D , Rauch, GM, Moulder, S & Yam, C 2023, 'Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy', Investigational New Drugs, vol. 41, no. 3, pp. 391-401. https://doi.org/10.1007/s10637-023-01357-4

@article{f8ad1cb357104ba28bbdad1df4ae0dd2,

title = "Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy",

author = "Nour Abuhadra and Ryan Sun and Bassett, {Roland L.} and Lei Huo and Chang, {Jeffrey T.} and Mediget Teshome and Clayborn, {Alyson R.} and White, {Jason B.} and Ravenberg, {Elizabeth E.} and Adrada, {Beatriz E.} and Candelaria, {Rosalind P.} and Wei Yang and Qingqing Ding and Symmans, {W. Fraser} and Banu Arun and Senthil Damodaran and Koenig, {Kimberly B.} and Layman, {Rachel M.} and Bora Lim and Litton, {Jennifer K.} and Alastair Thompson and Ueno, {Naoto T} and Helen Piwnica-Worms and Hortobagyi, {Gabriel N.} and Vicente Valero and Debu Tripathy and Rauch, {Gaiane M.} and Stacy Moulder and Clinton Yam",

note = "Funding Information: Funding and drug support were provided (in part) by Novartis AG; Pfizer Inc. This work was funded by generous philanthropic contributions to the Moon Shots Program of The University of Texas MD Anderson Cancer Center, the Still Water Foundation (to D. Tripathy), and the Winterhof fund (to S.L. Moulder). Pre-sequencing processing work was completed by the Cancer Genomics Laboratory Moon Shots Platform and the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center. Sequencing and data generation was supported by the CA016672 grant from The University of Texas MD Anderson Cancer Center. Dr. Yam was additionally supported by a Conquer Cancer Career Development Award supported by Fleur Fairman, the 2018 Gianni Bonadonna Breast Cancer Research Fellowship (Conquer Cancer Foundation), the Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, and the Susan Papizan Dolan Fellowship in Breast Oncology. Dr. Chang was supported by the Cancer Prevention Research Institute of Texas (RP170668, RP160710) and the National Institutes of Health{\textquoteright}s National Cancer Institute (U54CA209978). Any opinions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of the sponsors. ",

year = "2023",

month = jun,

doi = "10.1007/s10637-023-01357-4",

language = "English (US)",

volume = "41",

pages = "391--401",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer

T2 - a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy

AU - Abuhadra, Nour

AU - Sun, Ryan

AU - Bassett, Roland L.

AU - Huo, Lei

AU - Chang, Jeffrey T.

AU - Teshome, Mediget

AU - Clayborn, Alyson R.

AU - White, Jason B.

AU - Ravenberg, Elizabeth E.

AU - Adrada, Beatriz E.

AU - Candelaria, Rosalind P.

AU - Yang, Wei

AU - Ding, Qingqing

AU - Symmans, W. Fraser

AU - Arun, Banu

AU - Damodaran, Senthil

AU - Koenig, Kimberly B.

AU - Layman, Rachel M.

AU - Lim, Bora

AU - Litton, Jennifer K.

AU - Thompson, Alastair

AU - Ueno, Naoto T

AU - Piwnica-Worms, Helen

AU - Hortobagyi, Gabriel N.

AU - Valero, Vicente

AU - Tripathy, Debu

AU - Rauch, Gaiane M.

AU - Moulder, Stacy

AU - Yam, Clinton

N1 - Funding Information: Funding and drug support were provided (in part) by Novartis AG; Pfizer Inc. This work was funded by generous philanthropic contributions to the Moon Shots Program of The University of Texas MD Anderson Cancer Center, the Still Water Foundation (to D. Tripathy), and the Winterhof fund (to S.L. Moulder). Pre-sequencing processing work was completed by the Cancer Genomics Laboratory Moon Shots Platform and the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center. Sequencing and data generation was supported by the CA016672 grant from The University of Texas MD Anderson Cancer Center. Dr. Yam was additionally supported by a Conquer Cancer Career Development Award supported by Fleur Fairman, the 2018 Gianni Bonadonna Breast Cancer Research Fellowship (Conquer Cancer Foundation), the Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, and the Susan Papizan Dolan Fellowship in Breast Oncology. Dr. Chang was supported by the Cancer Prevention Research Institute of Texas (RP170668, RP160710) and the National Institutes of Health’s National Cancer Institute (U54CA209978). Any opinions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of the sponsors.

PY - 2023/6

Y1 - 2023/6

UR - http://www.scopus.com/inward/record.url?scp=85152378308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85152378308&partnerID=8YFLogxK

U2 - 10.1007/s10637-023-01357-4

DO - 10.1007/s10637-023-01357-4

M3 - Article

C2 - 37043123

AN - SCOPUS:85152378308

SN - 0167-6997

VL - 41

SP - 391

EP - 401

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Cite this